7Baggers
 Published on: 2025-11-14 15:23:34  newser.com Fri, 14 Nov 2025 21:23:34 GMT
 Published on: 2025-11-13 13:02:19  newser.com Thu, 13 Nov 2025 19:02:19 GMT
 published on: 2025-11-13 05:55:22  newser.com Thu, 13 Nov 2025 11:55:22 GMT
 DBV Technologies stock surges after completing VITESSE trial  Investing.com Wed, 12 Nov 2025 14:16:22 GMT
 dbvt completes key phase 3 trial for peanut allergy treatment  GuruFocus Wed, 12 Nov 2025 11:44:54 GMT
 DBV Technologies completes last patient visit in VITESSE trial  Investing.com Wed, 12 Nov 2025 05:12:01 GMT
 DBV Technologies Announces Last Patient Visit Completed in  GlobeNewswire Wed, 12 Nov 2025 04:51:29 GMT
 published on: 2025-11-10 00:01:43  newser.com Mon, 10 Nov 2025 06:01:43 GMT
 published on: 2025-11-09 13:50:09  newser.com Sun, 09 Nov 2025 19:50:09 GMT
 published on: 2025-11-06 05:42:02  newser.com Thu, 06 Nov 2025 11:42:02 GMT
 published on: 2025-11-04 02:15:12  newser.com Tue, 04 Nov 2025 08:15:12 GMT
 dbv technologies s.a. (dbvt) analyst insights, price targets & recommendations  Yahoo! Finance Canada Tue, 04 Nov 2025 01:44:47 GMT
 information regarding the total number of voting rights  GlobeNewswire Mon, 03 Nov 2025 21:25:00 GMT
 north america, europe, and australia peanut allergy treatment  openPR.com Mon, 03 Nov 2025 09:33:56 GMT

DBV Technologies S.A
(NASDAQ:DBVT) 

DBVT stock logo

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergie...

Founded: 2002
Full Time Employees: 311
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends